Sanibel Captiva Trust Company Inc. Sells 13,754 Shares of Johnson & Johnson (NYSE:JNJ)

Sanibel Captiva Trust Company Inc. lessened its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 391,110 shares of the company's stock after selling 13,754 shares during the quarter. Johnson & Johnson accounts for 1.8% of Sanibel Captiva Trust Company Inc.'s investment portfolio, making the stock its 11th largest position. Sanibel Captiva Trust Company Inc.'s holdings in Johnson & Johnson were worth $56,562,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in JNJ. IFS Advisors LLC raised its position in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after acquiring an additional 100 shares during the period. Highline Wealth Partners LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter worth approximately $31,000. RPg Family Wealth Advisory LLC purchased a new position in Johnson & Johnson in the third quarter valued at approximately $35,000. Mowery & Schoenfeld Wealth Management LLC increased its position in Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock worth $40,000 after buying an additional 91 shares during the last quarter. Finally, Activest Wealth Management bought a new stake in shares of Johnson & Johnson in the third quarter valued at $40,000. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Wolfe Research started coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They issued an "outperform" rating and a $190.00 target price for the company. StockNews.com cut Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday. Morgan Stanley lifted their target price on Johnson & Johnson from $169.00 to $175.00 and gave the company an "equal weight" rating in a report on Wednesday, October 16th. Wells Fargo & Company raised their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an "equal weight" rating in a research report on Wednesday, October 16th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $174.29.

Insider Activity

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the business's stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares of the company's stock, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 0.16% of the company's stock.

Johnson & Johnson Trading Down 0.5 %

Shares of NYSE:JNJ traded down $0.74 on Monday, reaching $147.03. 10,678,393 shares of the company traded hands, compared to its average volume of 6,880,262. The stock has a market capitalization of $353.99 billion, a P/E ratio of 21.28, a price-to-earnings-growth ratio of 2.30 and a beta of 0.51. The business's 50-day simple moving average is $148.51 and its 200 day simple moving average is $156.10. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.37%. Johnson & Johnson's dividend payout ratio (DPR) is currently 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.